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FE and RE methods. CONCLUSIONS: Cisplatin significantly increased the RR of 
nephrotoxicity compared to non-cisplatin regimens when SCr was used to 
screen patients for inclusion in clinical trials, but only showed a trend toward a 
smaller increase in RR when GFR was used.  
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CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS OF COLORECTAL 
CANCER IN UNITED STATES VETERANS  
Wang L1, Zhang J1, Li L1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To examine the clinical characteristics and treatment patterns of 
colorectal cancer patients in the U.S. veteran population. METHODS: A study 
sample from the Veterans Health Administration (VHA) Medical SAS datasets 
from October 1, 2005 through May 31, 2012 was analyzed. All patients diagnosed 
with colorectal cancer throughout the study period were identified using 
International Classification of Disease 9thRevision Clinical Modification (ICD-9-
CM) diagnosis codes 153.xx and 154.xx. Descriptive statistical analyses were 
performed using SAS v9.3 software. RESULTS: There were 62,200 diagnosed 
colorectal cancer patients in the VHA population during the study period. Major 
comorbidities for these colorectal cancer patients were hypertension (n=18,309, 
29.44%) and diabetes (n=10,891, 17.51%). Other minor comorbidities included 
hyperlipidemia and benign neoplasm of the colon. Common treatments 
prescribed for colorectal cancer patients were simvastatin and omeprazole. 
Outpatient services were utilized by 99.71% of colorectal cancer patients, 
followed by pharmacy (91.94%) and inpatient visits (31.15%). Costs for outpatient 
($10,637, standard deviation [SD]=$17,125), pharmacy ($2,704, SD=$9,773), and 
inpatient services ($16,032, SD=$53,078) contributed to follow-up health care 
expenditures. Out of all colorectal cancer patients, 7,596 (12.21%) had Occult 
Blood (Fecal) Test results, with an average test result of 96.37. CONCLUSIONS: 
Colorectal cancer treatment is complicated by the presence of both major and 
minor comorbidities. Further analysis in the context of complicated comorbid 
conditions is required to improve the overall burden of illness of colorectal 
cancer patients.  
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OBJECTIVES: To examine the economic burden and clinical characteristics of 
lung cancer in the U.S. veteran population. METHODS: A retrospective database 
analysis was performed using the Veterans Health Administration (VHA) Medical 
SAS Datasets from October 1, 2005 to May 31, 2012. Patients with lung cancer 
were identified using International Classification of Disease 9th Revision Clinical 
Modification (ICD-9-CM) diagnosis code 162.xx. Descriptive statistics were 
calculated as means ± standard deviation (SD) and percentages to measure 
comorbidities, laboratory tests, costs and utilization distribution in the sample. 
Comorbidities and laboratory tests were measured for the 1-year baseline period 
before the disease identification date. Health care costs and utilization were 
measured for the 1-year follow-up period after the identification date. RESULTS: 
The total number of lung cancer patients identified in the study period was 
73,150. The most common comorbidities of these patients were hypertension 
(n=21,377, 29.22%), chronic airway obstruction (n=14,305, 19.56%), abnormal 
findings on radiological and other examination of lung field (n=12,437, 17.00%), 
and diabetes (n=11,569, 15.82%). Omeprazole and simvastatin were the top two 
most commonly prescribed treatments for lung cancer patients. Both 
medications were prescribed for more than 20% of all lung cancer patients. A 
total of 49,706 (67.95%) of the lung cancer patients had total white blood cell 
(WBC) count test results, averaging a result of 11.68. The percentage of patients 
with follow-up inpatient visits was 46.47%, which translated into $21,420 of 
inpatient costs per patient. 99.11% of patients had follow-up outpatient visits, 
which translated into $12,986 total outpatient costs per patient ($12,110 for office 
visit, $411 for emergency room visit costs). CONCLUSIONS: This study found that 
omeprazole and simvastatin were the most frequently prescribed drugs after a 
lung cancer diagnosis. However, more research is required to better understand 
adverse events and side effects.  
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RITUXIMAB FOR NON HODGKIN LYMPHOMA: OVERVIEW OF EFFICACY AND 
SAFETY  
Costa JO, Lemos LLP, Júnior AAG, Acurcio FA 
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil  
OBJECTIVES: To evaluate the efficacy and safety of the monoclonal antibody 
rituximab (RIT) for the treatment of patients with indolent or aggressive non-
Hodgkin lymphoma B cells (B-NHL). METHODS: We searched The Cochrane 
Library, Centre for Reviews and Dissemination, Tripdatabase, Medline and 
LILACS databases aiming to find systematic reviews (SR) and randomized clinical 
trials (RCT) comparing RIT regimens versus RIT free regimens for induction or 
maintenance treatment of indolent and aggressive B-NHL. Health Technology 
Assessments (HTA) were searched on agencies websites. Quality of the evidence 
and strength of recommendation were evaluated using the GRADE system. 
RESULTS: We selected thirteen SR, eight RCT and six HTA publications. Half of 
the SR and the majority of RCT were classified as poor quality. The strength of 
recommendation was considered weak in favor of RIT in all studies. Combined 
overall survival meta-analysis showed a relative risk of 1.09 (1.06; 1.12) benefiting 
RIT treated patients. Overall survival for aggressive NHL non-RIT treated patients 
was 0.53 (0.37; 0.77). The death hazard ratio for indolent B-NHL RIT treated 
patients were 0.65 (0.54; 0.78) and 0.76 (0.62; 0.92). Individual studies also showed 
benefits of increased overall survival for RIT treated patients. The studies 
showed a higher incidence of serious adverse events with RIT regimens, such as 
granulocytopenia and leucopenia, which did not appear to lead to increased 
infections or mortality rates. HTA publications recommended the use of RIT 
regimens as first-line therapy for aggressive and indolent B-NHL or as second-
line therapy and maintenance for indolent B-NHL. CONCLUSIONS: Evidences 
support the use of RIT in combination with chemotherapy as first-line and 
second-line treatment for aggressive B-NHL. For patients with follicular indolent 
B-NHL, RIT is recommended in combination with chemotherapy for patients 
previously treated or not, and for the maintenance of patients who responded to 
treatment after second-line chemotherapy.  
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SYSTEMATIC REVIEW OF ANTI-VEGF THERAPIES FOR METASTATIC 
COLORECTAL CANCER  
Aggarwal S, Segal J 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Anti-angiogenic therapy has become an integral component of 
treatment for metastatic colorectal cancer patients. During the last 10 years, 
several studies were conducted to test the safety and efficacy of anti-angiogenic 
therapies in mCRC patients. This study reviewed the results of randomized 
controlled trials published in peer-reviewed journals. METHODS: We searched 
the MEDLINE, and abstracts from ECCO, ESMO and ASCO until January 2013. 
Studies were selected for randomized controlled trials on targeted anti-
angiogenic drugs in mCRC. Primary endpoints reviewed were progression-free 
(PFS) and overall survival (OS). Response rates, toxicity and secondary 
resectability were secondary endpoints. Aggregated data were further analyzed 
to understand comparative safety and efficacy. RESULTS: Until January 2013, 
eligible mCRC randomized clinical trials for this review were available for 
bevacizumab (6 trials including 4523 patients), Cediranib ( 2 trials including 2282 
patients), vatalanib (2 trials including 2033 patients) and aflibercept (1 trial 
including 1226 patients). Overall, anti-angiogenesis therapy for mCRC shows 
significant OS and PFS benefit versus comparators. The median OS and PFS 
benefit for regimens containing Bevacizumab were 3 and 3.15 months, versus 
background chemotherapy. The median OS and PFS benefit for vatalanib 
containing regimens were statistically insignificant versus background 
chemotherapy. CONCLUSIONS: Anti-angiogenesis therapy with Bevacizumab for 
mCRC shows significant OS and PFS benefit versus comparators.  
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OBJECTIVES: Breast cancer is the most common cancer in women as well as the 
principle cause of death from cancer among women worldwide. Approximately 
20%–30% of women with breast cancer over-express the human epidermal 
growth factor receptor 2 (HER2), which promotes the growth of cancer 
cells.Trastuzumab is a recombinant humanized monoclonal antibody that 
targets HER2. It has been shown to be effective as monotherapy and, as adjuvant 
therapy, has been shown to improve results of chemotherapy in patients with 
HER2-positive metastatic breast cancer. The objective of this study was to 
conduct a meta-analysis of the available evidence on the benefit of receiving 
adjuvant trastuzumab in HER2-positive breast cancer patients who are 
concomitantly receiving chemotherapy. METHODS: We performed a literature 
search in MEDLINE® (1996 to 2012) to find peer-reviewed publications and 
academic conference proceedings relevant to the objective. A meta-analysis of 
randomized controlled trials comparing chemotherapy patients with or without 
adjuvant trastuzumab treatment was conducted. The primary outcome was 
disease-free survival (DFS), while a secondary outcome was mortality. Both the 
random-effects model and the fixed-effect model were used to combine and 
analyze data. RESULTS: Six eligible clinical trials were identified, and 14,299 
patients with HER2-positive breast cancer were included. Results indicated 
superior outcomes in the adjuvant trastuzumab group relative to the group 
without trastuzumab. For DFS, the trastuzumab group had an odds ratio (OR) of 
0.62 (95% CI: 0.48-0.80).For mortality, it had an OR of 0.77 (95% CI: 0.64-0.93). 
CONCLUSIONS: According to the meta-analysis, adjuvant trastuzumab therapy 
both improves DFS and reduces mortality relative to patients treated with 
chemotherapy only. Other issues surrounding trastuzumab include optimum 
length of therapy, the high cost of therapy, and the high risk of cardiovascular 
side effects, which may themselves lead to death.  
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SORAFENIB FOR KIDNEY CANCER: EVIDENCE OF EFFICACY, SAFETY AND COST 
ESTIMATES  
Barbosa MM, Almeida AM, Costa JDO, Júnior AG, Acurcio FA 
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil  
OBJECTIVES: Evaluate the efficacy, safety and cost estimates of sorafenib 
compared to other therapeutic options for the treatment of metastatic renal cell 
carcinoma (mRCC). METHODS: Systematic reviews (SR) of clinical trials 
comparing sorafenib with other therapeutic options were searched in The 
Cochrane Library, Medline, Lilacs, Centre for Reviews and Dissemination and 
Tripdatabase. We also selected health technology assessments (HTA) reports. 
Monthly treatment costs of the inhibitors of vascular endothelial growth factor 
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(anti-VEGF) were estimated based on prices established by Brazilian Drug Market 
Regulation Chamber. RESULTS: Nine studies were included: eight SR and one 
HTA. All reviews showed weak strength of recommendation and moderate to 
high quality of evidence. Sorafenib showed a median progression free-survival 
time around 6 months and was more effective than placebo, equally effective 
than interferon, and less effective than sunitinib. Patients who received 
sorafenib had a higher risk of suffering major adverse events. The cost of 
monthly treatment with anti-VEGF: sorafenib, sunitinib, temsirolimus, 
bevacizumab and interferon alpha was US$ 4.090,40, US$ 7.017,83, US$ 4.619,26, 
US$ 8.037,17 and US$ 3.166,67, respectively. CONCLUSIONS: Based on the 
available evidence, the increased survival caused by anti-VEGF is modest and 
based on weak evidence level, therefore with little clinical value. In addition, 
treatment with anti-VEGF is associated with serious adverse events and shows 
high cost. Hence we recommend the use of these drugs only when the surgical 
procedure isn’t indicated. All studies include patients with mCCR of clear cell, so 
it´s unclear whether the results can be extrapolated to patients with other stages 
and subtypes of RCC.  
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QUALITY INDICATORS OF THE THIRD SCREENING ROUND (2006-2007) OF THE 
HUNGARIAN ORGANIZED, NATIONWIDE BREAST CANCER SCREENING 
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Boncz I1, Dobrossy L2, Péntek Z3, Kovács A2, Budai A2, Vajda R1, Sebestyén A4 
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group  
45-65 years are the target population and 2 years screening interval is applied. 
The aim of this study is to evaluate the quality indicators of the 3rd screening 
round (2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated the following indicators: recall rate of women who 
underwent mammography examinations, attendance of re-called women, 
proportion of women referred to surgery, proportion of women who underwent 
surgery compared to referred women, proportion of benign and malign cases. 
RESULTS: In 2006-2007 there were 453142 screening mammography 
examinations in Hungary. 5.48% of participating women were re-called. The 
attendance of re-called women was 92.6%. Altogether 2087 women (9.6%) were 
referred for breast surgery but only 1503 women (72.0%) underwent surgery. 
Histological examination confirmed 379 benign (25.2%) and 1124 malign (74.8%) 
cases. CONCLUSIONS: The quality indicators of the Hungarian organized 
mammography screening program met the recommendations of international 
professional guidelines. However, in addition to current indicators, new ones 
should be introduced in order to provide a more comprehensive monitoring of 
the program.  
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OBJECTIVES: Organized, nationwide screening for breast cancer with 
mammography started in Hungary in January 2002. Women in the age group 45-
65 years are the target population and 2 years screening interval is applied. The 
aim of this study is to analyze the attendance rate of the 3rd screening round 
(2006-2007). METHODS: The data derive from the financial database of the 
National Health Insurance Fund Administration (NHIFA) covering the period of 
2006-2007. We calculated two attendance indicators. The up-take of the program 
means the percentage of women aged 45-65 who, having been sent an invitation 
for screening, attend a screening unit and undergo mammography in response 
to that invitation. We defined coverage as the ratio of women in the age group 
45-65 years having either a screening mammography or a diagnostic 
mammography. RESULTS: In 2006-2007 there were 453142 screening 
mammography cases and 1248183 diagnostic mammography examinations in 
Hungary. We found 41.7% and 52.5% up-take in 2006 and 2007 respectively; and 
46.3% combined rate for 2006/2007. The screening coverage was 29.2% and the 
diagnostic coverage was 21.6%, while the total coverage (screening and 
diagnostic) was 49.3%. CONCLUSIONS: The attendance of the Hungarian 
organized breast cancer screening program – compared to the previous period 
before the implementation of the organized screening program – is promising, 
although to achieve the expected results in mortality decrease a further 
improvement of both the uptake and coverage is necessary.  
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OBJECTIVES: To examine the impact of palonosetron versus other 5-HT3 RAs on 
incidence of delayed CINV at cycle 1 based on presence of certain risk factors 
(age <50 years, female gender, prior CINV, anxiety, no or minimal alcohol use, 
history of motion sickness, and emetogenicity of chemotherapy). METHODS: A 
retrospective claims analysis was conducted using OptumInsight database from 
December 1, 2005 to June 30, 2011. Continuously enrolled cancer patients >18 
years of age initiated on their first chemotherapy (index date) were included. 
Patients with a previous cancer diagnosis in the pre-index period or receiving 
multi-day chemotherapy were excluded. The study population was examined for 
differences in CINV rates by each 5-HT3 RA stratified by number of risk factors 
(female gender, age <50, previous anxiety, vomiting pre-index, and highly 
emetogenic chemotherapy. CINV was identified using ICD9CM codes for nausea, 
vomiting, or related events, and rescue medication use within 5 days after 
chemotherapy. RESULTS: Final analysis included 26,974 patients. Overall the 
percentage of patients experiencing CINV increased as the number of risk factors 
increased – 13.5%, 14.9%, 15.6%, and 18.4% for 0, 1, 2, and 3 or more risk factors, 
respectively. High-risk patients (3 or more risk factors) receiving palonosetron 
had less CINV events compared to ondansetron, granisetron, and dolasetron. 
Odds Ratios (OR) 95%CI versus palonosetron were 1.523 (1.231, 1.883), 1.426 
(1.146, 1.773), and 1.683 (1.271, 2.229), respectively. CONCLUSIONS: The 
probability of a CINV event increased with the accumulation of identified risk 
factors. Palonosetron demonstrated a statistically significant OR versus all other 
5-HT3 RA in patients at the highest risk of developing a CINV event.  
 
PCN12  
META-ANALYSIS OF THE EFFICACY AND SAFETY OF BORTEZOMIB (BTZ) 
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OBJECTIVES: BTZ is administered for a finite course; thus, MM pts may remain 
sensitive to BTZ-based therapy at relapse. We conducted a meta-analysis to 
assess efficacy and safety of BTZ-based retreatment in studies of pts with 
relapsed (rel) and/or refractory (ref) MM. METHODS: The proportion of BTZ-ref 
pts was identified where available. Other prognostic factors were extracted and 
used in weighted stratified analyses of TTP, PFS, and OS. Random-effect pooled 
estimates were calculated for ORR (≥PR) and rates of common AEs. RESULTS: 
Twenty-three studies (N=1051 pts) were identified. BTZ was given IV in all 
studies. Retreatment comprised BTZ±dex in 4 studies and BTZ-based 
combination therapy in 19. BTZ-ref pts were included in 11 studies; 6 studies 
included only rel pts. Across studies with data available, pooled, weighted 
average ORR was 39% (95% CI: 31–47) and median TTP, PFS, and OS were 7.5, 5.8, 
and 16.6 months. Stratified univariate analyses showed outcomes were generally 
consistent across groups while pts with ≤4 prior therapies and rel (but not ref) 
pts had higher ORRs of 43% and 57%, respectively. By random-effects meta-
regression analysis, compared to ref pts, rel pts were associated with a higher 
ORR by 28–41 percentage points. The most common grade 3/4 AEs were 
thrombocytopenia (35%), neutropenia (15%), anemia (14%), pneumonia (10%), and 
peripheral neuropathy (3%). CONCLUSIONS: Based on these findings, BTZ 
retreatment is efficacious and well tolerated in rel pts. In an era of new and 
emerging treatment options, these data indicate BTZ retreatment continues to 
be a highly effective option in previously treated pts.  
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BACKGROUND: Prior to the March 25, 2011 FDA-approval of ipilimumab (ipi), 
clinical trial data indicated that no drug treatment (tx) for advanced melanoma 
(AM) (unresectable or metastatic melanoma) led to an improvement in overall 
survival (OS). OBJECTIVES: To further explore the relationship between OS and 
the treatments available for AM patients prior to ipi approval by examining real 
world (RM) data. METHODS: Baseline characteristics, tx and outcomes of 752 
newly diagnosed AM pts (2004-2008) were collected from the medical charts of a 
nationally representative random sample of 113 U.S. oncologists. Follow-up of 
survival outcomes concluded on the date of ipi approval. OS from AM diagnosis 
to 1 and 2 years were described by stage and by whether pts were incident (no 
prior melanoma) or recurrent (AM diagnosis after early-stage melanoma). To 
determine change in outcomes over time, current OS of incident pts was 
compared to published data on a prior cohort of pts from the AJCC registry, 
staged at initial melanoma diagnosis (Balch 2001). RESULTS: One-year (39.8%, 
95% CI=[34.2-45.3%]) and 2-year (27.6%, 95% CI=[22.4-32.8%]) survival rates among 
incident Stage IV pts were statistically similar to weighted averages (by 
metastasis classification) from the AJCC registry. Incident unresectable Stage III 
pts had lower OS rates than the weighted average of all Stage III pts from the 
AJCC registry (which included both resectable and unresectable pts). 
CONCLUSIONS: These real-world data show that incident metastatic melanoma 
pts diagnosed from 2004 to 2008 had OS similar to the AJCC registry pts—who 
were diagnosed in prior decades—and confirm the limitations of AM tx prior to 
ipi approval. Future research should examine OS in real-world AM pts following 
ipi approval.  
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CALENDAR TIME AS AN INSTRUMENTAL VARIABLE IN NONEXPERIMENTAL 
COMPARATIVE EFFECTIVENESS RESEARCH OF EMERGING THERAPIES  
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Hospital, Boston, MA, USA  
OBJECTIVES: Colon cancer (CC) is primarily a disease of older individuals, with 
65.3% of incident cases in the United States occurring in those aged 65 and 
